Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Veterinary Rabies Vaccines Market

Veterinary Rabies Vaccines Market Share

Report ID: GMI10816
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Veterinary Rabies Vaccines Market Share

The competitive landscape of the market is characterized by a dynamic and rapidly evolving environment with several key players vying for market share. Leading pharmaceutical companies, such as Merck Animal Health, Zoetis, and Boehringer Ingelheim, dominate the market with their established portfolios of rabies vaccines and extensive distribution networks. These companies invest heavily in research and development to enhance vaccine efficacy, safety, and longevity.

The market is further shaped by strategic partnerships, mergers, and acquisitions aimed at expanding product offerings and geographic reach. Additionally, increasing awareness of rabies prevention in veterinary practice and rising government initiatives for animal health contribute to a competitive atmosphere where continuous innovation and cost-effective solutions are crucial for market success.

Veterinary Rabies Vaccines Market Companies

Few of the prominent players operating in veterinary rabies vaccines industry include:

Biogénesis Bago S.A.
Bioveta, a.s.
Boehringer Ingelheim International GmbH
Ceva Santé Animale S.A.
Dyntec
Elanco Animal Health Incorporated
Indian Immunologicals Limited
Merck & Co., Inc.
Vaxxinova International B.V.
Virbac S.A.
Zoetis Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The veterinary rabies vaccines market was valued at USD 502.5 million in 2023 and is anticipated to grow at 4.2% CAGR between 2024 – 2032, driven primarily by the increasing prevalence of rabies in animals.

The companion animals segment of the market was worth USD 264.6 million in 2023 and will grow rapidly through 2032, driven by the growing awareness among pet owners about the importance of rabies vaccination.

North America veterinary rabies vaccines market was valued at USD 197.6 million and is projected to grow at 3.8% CAGR from 2024 to 2032, driven by a robust veterinary healthcare infrastructure.

Biogénesis Bago S.A, Bioveta, Boehringer Ingelheim International GmbH, Ceva Santé Animale S.A, Dyntec, Elanco Animal Health Incorporated, Indian Immunologicals Limited among others.